共 50 条
- [21] Treatment with vemurafenib in patients with metastatic melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Ocvirk, JanjaBoc, MarkoMesti, TanjaRebersek, Martina
- [22] Phase I trial evaluating concurrent vemurafenib and ipilimumab in patients with advanced BRAF-mutant melanomaEUROPEAN JOURNAL OF CANCER, 2013, 49 : S867 - S867Ribas, A.Hodi, F. S.Callahan, M.Chmielowski, B.Lawrence, D.Konto, C.McHenry, M. B.Choong, N.Wolchok, J.
- [23] Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)Zakharia, YousefMcWilliams, Robert R.Rixe, OlivierDrabick, JosephShaheen, Montaser F.Grossmann, Kenneth F.Kolhe, RavindraPacholczyk, RafalSadek, RamsesTennant, Lucinda L.Smith, Christopher M.Kennedy, Eugene P.Link, Charles J., Jr.Vahanian, Nicholas N.Yu, JiayiShen, Steven S.Brincks, Erik L.Rossi, Gabriela R.Munn, DavidMilhem, Mohammed
- [24] Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Milhem, Mohammed M.Zarour, Hassane M.Gabrail, Nashat Y.Mauro, David J.Greenberg, Norman M.Slichenmyer, William J.Krieg, Arthur M.
- [25] Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Marquez-Rodas, IvanDalle, StephaneCastanon, EduardoSanmamed, Miguel F.Arance, Ana MariaCerezuela-Fuentes, PabloHuertas, Roberto MartinRodriguez-Moreno, Juan FranciscoGonzalez-Cao, MariaMunoz-Couselo, EvaMartin-Liberal, JuanRodriguez-Abreu, DelvysAlberich-Bayarri, AngelMayorga-Ruiz, IreneVila, Miguel Angel MolinaRoman, RuthChaney, Marya F.Lopez, Javier SanchezMacia, SoniaQuintero, Marisol
- [26] A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Edenfield, William JefferyBecerra, CarlosBraiteh, Fadi S.Spira, Alexander I.Sullivan, Ryan J.Panella, Timothy J.Li, WeiHuang, JanetLi, YouzhiFlaherty, KeithHitron, MatthewLi, Chiang
- [27] Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic MelanomaACTA DERMATO-VENEREOLOGICA, 2022, 102Batinac, TanjaHlaca, NikaSimetic, LukaValkovic, FranePeternel, SandraPrpic-Massari, Larisa
- [28] A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma.JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 404 - 404Trefzer, UWeingart, GAdrian, KChen, YGuo, YJAudring, HWinter, HWalden, PSterry, W
- [29] Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b studyLANCET ONCOLOGY, 2014, 15 (09): : 954 - 965Ribas, AntoniGonzalez, RenePavlick, AnnaHamid, OmidGajewski, Thomas F.Daud, AdilFlaherty, LawrenceLogan, TheodoreChmielowski, BartoszLewis, KarlKee, DamienBoasberg, PeterYin, MingChan, IrisMusib, LunaChoong, NicholasPuzanov, IgorMcArthur, Grant A.
- [30] Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Svane, Inge MarieNair, Santosh M.Puzanov, IgorRobert, CarolineHassel, Jessica CecileSandhu, ShahneenChristiansen, Anita VedelLowery, KathPemberton, KristineAl Hajj, MohammadDiede, Scott J.Ehrnrooth, EvaEggermont, Alexander M.